Position in NVS
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$770,277
+$5,916 QoQ
Shares Held
4,915
-1.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#711
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 84%
Shared 0%
None 16%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CARY STREET PARTNERS FINANCIAL LLC holds $153,520,894 across 14 Drug Manufacturers - General names. NVS ranks #10 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
30,891 | $37,051,594 | |
| 2 | JNJ |
Johnson & Johnson
|
139,478 | $35,423,227 | |
| 3 | ABBV |
AbbVie Inc.
|
132,877 | $33,437,167 | |
| 4 | MRK |
Merck & Co., Inc.
|
201,087 | $25,839,679 | |
| 5 | AMGN |
Amgen Inc
|
17,422 | $6,308,854 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
104,335 | $6,011,782 | |
| 7 | PFE |
Pfizer Inc
|
153,898 | $3,705,863 | |
| 8 | AZN |
Astrazeneca PLC
|
13,070 | $2,478,333 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $770,277 | 4,915 | Shares | Defined | 2026-07-17 | |
| 2026-03-31 | $764,361 | 5,004 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $686,868 | 4,982 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $789,701 | 6,158 | Shares | Defined | 2025-11-10 | |
| 2025-06-30 | $796,124 | 6,579 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $752,378 | 6,749 | Shares | Defined | 2025-05-09 | |
| 2024-12-31 | $791,713 | 8,136 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||